CHARLES RIVER LABORATORIES INTERNA (CRL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CRL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CRL | Chief Executive Officer of Rapport Therapeutics | 48 | ["nearly two decades of executive and public company biopharmaceutical industry experience"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PCRX | Chief Executive Officer, Rapport Therapeutics, Inc. | 47 | ["Business Development / M&A", "Human Capital Management", "Industry Experience", "Operations, Manufacturing & Supply Chain", "Research & Development"] | ["Audit", "People & Compensation"] | 2025 |
Biography sourced from the proxy statement filing.
Chief Executive Officer of Rapport Therapeutics. Prior to joining Rapport, he served as President of Cerevel Therapeutics from May 2021 through February 2023. Earlier, he was the CEO of Tiburio Therapeutics, where he built a fully integrated organization and advanced a program to investigational new drug (IND) enablement for a rare neuroendocrine tumor. Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme. Mr. Ceesay serves on the boards of Rapport Therapeutics, Pacira Biosciences, and Life Science Cares, as well as on the Board of Trustees of Thayer Academy. Mr. Ceesay has been a director since May 2025. Mr. Ceesay s qualifications to serve as a director include his nearly two decades of executive and public company biopharmaceutical industry experience.